Evaluation of cardiometabolic risk markers linked to reduced left ventricular ejection fraction (LVEF) in patients with ST-elevation myocardial infarction (STEMI). 2022

Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

It is well established that left ventricular systolic dysfunction (LVSD), as marked by reduced left ventricular ejection fraction (LVEF), notably worsens the prognosis of ST-elevation myocardial infarction (STEMI). However, the link between cardiometabolic risk markers and LVSD seems unclear. This study aimed to investigate the differences in variables affecting reduced LVEF in STEMI patients. In the current retrospective study, 200 consecutive STEMI patients were enrolled between April 2016 to January 2017. Analysis of serum parameters, anthropometric evaluation, and echocardiography was performed after admission. The participants were categorized according to LVEF levels as follows: group1 (normal: 50-70%, n = 35), group2 (mildly reduced: 40-49%, n = 48); group3 (moderately reduced: 30-39%, n = 94) and group4 (severely reduced: < 30%, n = 23). Between-group comparisons were made using the Kruskal-Wallis test. Overall, of 200 STEMI patients with a mean age of 62 years, 27%(n = 54) were females. The median of BMI of patients in group4 (31.07 kg/m2) was significantly higher than group3 (26.35 kg/m2), group2 (25.91 kg/m2), and group1 (24.98 kg/m2; P value < 0.0001). Group4 patients showed significantly increased fasting blood sugar (FBS) than groups 1 (212.00, vs. 139.00 mg/dl; P value = 0.040). Patients in groups 1 and 2 exerted significantly elevated triglyceride levels than those in group4 (142.00, 142.50, and 95.00 mg/dl; P value = 0.001). WBC count, neutrophil%, and neutrophil to lymphocyte ratio among those in group1 (10,200/m3, 70.00%, and 2.92, respectively) were significantly lower than group4 (12,900/m3, 83.00%, and 5.47, respectively; P value < 0.05). These findings highlight higher BMI, FBS, and leucocyte count linked to LVSD, probably through increasing the inflammation and reducing LVEF levels. More extensive studies are needed to clarify the clinical relevance of these results.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072657 ST Elevation Myocardial Infarction A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION). ST Elevated Myocardial Infarction,ST Segment Elevation Myocardial Infarction,STEMI
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013318 Stroke Volume The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume. Ventricular Ejection Fraction,Ventricular End-Diastolic Volume,Ventricular End-Systolic Volume,Ejection Fraction, Ventricular,Ejection Fractions, Ventricular,End-Diastolic Volume, Ventricular,End-Diastolic Volumes, Ventricular,End-Systolic Volume, Ventricular,End-Systolic Volumes, Ventricular,Fraction, Ventricular Ejection,Fractions, Ventricular Ejection,Stroke Volumes,Ventricular Ejection Fractions,Ventricular End Diastolic Volume,Ventricular End Systolic Volume,Ventricular End-Diastolic Volumes,Ventricular End-Systolic Volumes,Volume, Stroke,Volume, Ventricular End-Diastolic,Volume, Ventricular End-Systolic,Volumes, Stroke,Volumes, Ventricular End-Diastolic,Volumes, Ventricular End-Systolic
D016277 Ventricular Function, Left The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance. Left Ventricular Function,Function, Left Ventricular,Functions, Left Ventricular,Left Ventricular Functions,Ventricular Functions, Left
D062645 Percutaneous Coronary Intervention A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting. Percutaneous Coronary Revascularization,Coronary Intervention, Percutaneous,Coronary Interventions, Percutaneous,Coronary Revascularization, Percutaneous,Coronary Revascularizations, Percutaneous,Intervention, Percutaneous Coronary,Interventions, Percutaneous Coronary,Percutaneous Coronary Interventions,Percutaneous Coronary Revascularizations,Revascularization, Percutaneous Coronary,Revascularizations, Percutaneous Coronary

Related Publications

Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
October 2016, International journal of cardiology,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
April 2022, European heart journal. Cardiovascular Imaging,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
March 2008, American heart journal,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
July 2016, International journal of cardiology,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
May 2019, JACC. Cardiovascular imaging,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
January 2019, Journal of postgraduate medicine,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
July 2023, The American journal of cardiology,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
May 2017, Coronary artery disease,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
January 2013, Swiss medical weekly,
Marjan Mahdavi-Roshan, and Zeinab Ghorbani, and Mahboobeh Gholipour, and Arsalan Salari, and Amir Savar Rakhsh, and Jalal Kheirkhah
January 2017, PloS one,
Copied contents to your clipboard!